Androgenic alopecia currently exhibits a growing pipeline with approximately 24 active drug candidates, P&S Market Research
Androgenic Alopecia Therapeutics Pipeline in 2017
The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development. Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both the sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and toxins.
Various Technologies are Being Used for Androgenic Alopecia
According to the research findings, various new technology platforms are being used by the companies for developing drug candidates to treat the disease. For instance, KINect technology platform, a kinase-focused drug discovery technology platform is used to manufacture, soft Janus kinase inhibitors, a Pre-Clinical drug candidate by Aclaris Therapeutics, Inc.
Access Research Report with Detailed TOC on "Androgenic Alopecia” Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" at: https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis
Positive Clinical Results of Androgenic Alopecia Therapeutics Candidates
The positive clinical results of androgenic alopecia drug candidates have been driving the pipeline growth. Many drug candidates have shown positive clinical results and are proceeding further towards development. In February 2016, Cassiopea S.p.A. reported the top-line results from the proof of concept, Phase II clinical trial of Breezula (CB-03-01), in androgenic alopecia and it was found that Breezula, met both its two pre-defined co-primary efficacy endpoints, increase in total area hair count within 1 cm2 (TAHC) and subject hair growth assessment (HGA) at six months. Breezula also demonstrated favorable safety profile.
Various Collaborations for Androgenic Alopecia Therapeutics Drug Development
In August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a privately held biotechnology company for a consideration of $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date to expand the dermatological pipeline of Aclaris Therapeutics, Inc.
Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.
Androgenic Alopecia Therapeutics Pipeline Analysis